Lyfgenia (lovotibeglogene autotemcel) — Prior Authorization and Coverage Criteria
Customize your policy alerts
Sign up for all husky_health policy alerts
Know when husky_health releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization policy for one-time administration of Lyfgenia for eligible Connecticut Medicaid (HUSKY Health) members with sickle cell disease; describes medical necessity criteria, required documentation, and procedural requirements for providers.
Removed criteria specifying SCD genotypes and reference to α globin gene deletions; changed 'authorized' treatment center to 'qualified' treatment center; clarified VOE history requirement and other eligibility refinements.
Coverage and Medical Necessity
Medical Necessity Criteria
Treatment with Lyfgenia will be considered medically necessary when ALL of the following are met:
Exclusions listed explicitly in policy
Individuals being considered for Lyfgenia must not have specified exclusionary conditions. Exclusions include advanced liver disease; any active bacterial, viral, fungal, or parasitic infection (explicitly including active HIV‑1, HIV‑2, hepatitis B, or hepatitis C); any prior or current malignancy, myeloproliferative disorder, or significant immunodeficiency disorder; or a history or presence of Moyamoya disease. These exclusions are applied during eligibility determination for hematopoietic stem cell transplant and Lyfgenia treatment.
Paragraphs in the medical necessity criteria also require that the individual has not previously received a hematopoietic stem cell transplant and has not previously received Lyfgenia or any other gene therapy; additionally, patients must have trialed at least one pharmacologic treatment for SCD and the treating provider must follow all FDA recommendations for use, dosing, preparation, administration, monitoring, and patient education.
Lyfgenia is considered investigational and not medically necessary for all indications not specified in this policy. Requests for use outside the defined eligibility criteria are not supported by this policy and should be considered non‑covered.
Lyfgenia is approved as a one‑time infusion only. Repeat administration of Lyfgenia is not considered medically necessary, as repeat dosing is not supported by FDA labeling or compendia.
Billing, Codes, and Eligibility Metrics
| J3394 | Injection, lovotibeglogene autotemcel, per treatment |
Provider Requirements, Prior Authorization, and Documentation
Prior authorization required — ordering physician must submit Lyfgenia PA form before administration
Prior authorization must be obtained before administration. Requests for prior authorization must be submitted by the ordering physician using the State of Connecticut, Department of Social Services HUSKY Health Lyfgenia Prior Authorization Request form (faxed to the number on the form). If approved, authorization covers a one-time, single-dose IV infusion of Lyfgenia (J3394).
- Submit by the ordering physician
- Use the HUSKY Health Lyfgenia Prior Authorization Request form
- Fax to the number listed on the request form
- Approval authorizes a one-time, single-dose IV infusion
Prior pharmacologic therapy required — trial of ≥1 SCD medication
The individual must have previously trialed at least one pharmacologic treatment for sickle cell disease prior to approval; examples listed in the policy include hydroxyurea, l‑glutamine, crizanlizumab‑tmca, or voxelotor.
- Examples of acceptable prior pharmacologic therapies: hydroxyurea; l‑glutamine; crizanlizumab‑tmca; voxelotor
Required documentation for PA — completed form plus clinical records
The PA submission must include the fully completed HUSKY Health Lyfgenia Prior Authorization Request form (including physician order and signature) plus clinical documentation supporting medical necessity.
- Fully completed Lyfgenia Prior Authorization Request form with physician order and signature
- Confirmatory genetic testing
- Medical records documenting ≥4 VOEs in the prior 2 years OR documentation of current chronic transfusion therapy for recurrent VOEs
- Medical record documentation of prior pharmacologic therapies trialed for SCD
- Signed provider attestation confirming HSCT eligibility and that the individual has not previously received HSCT or any gene therapy
Authorization and documentation risk — lack of PA or insufficient documentation may lead to denial
Failure to obtain prior authorization or to provide the required supporting documentation may result in denial of the request.
- Authorization is based on medical necessity at time issued and is not a guarantee of payment
- Insufficient documentation (see required documentation list) can lead to denial
Background
Sickle cell disease (SCD) is an inherited single‑gene disorder characterized by predominance of hemoglobin S (HbS) leading to hemolytic anemia and vaso‑occlusion. Lyfgenia (lovotibeglogene autotemcel) is an autologous hematopoietic stem cell–based gene addition therapy that delivers modified anti‑sickling adult hemoglobin (HbA T87Q) to reduce intracellular and total HbS and inhibit HbS polymerization, with the goal of decreasing vaso‑occlusive events and related complications. Treatment with Lyfgenia requires specialist involvement, administration at a qualified treatment center, and meeting the policy’s clinical eligibility criteria (age, VOE history or chronic transfusion requirement, prior therapy trials, and absence of exclusionary conditions).
Product Definition
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.